Sesen Bio's stock rocked on heavy volume after shock FDA decision on BLA for cancer treatmentMarket Watch • 08/13/21
Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)Business Wire • 08/13/21
Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™Business Wire • 08/11/21
Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™Business Wire • 08/09/21
Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in TurkeyBusiness Wire • 08/05/21
Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™Business Wire • 08/02/21
Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the USBusiness Wire • 07/26/21
Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in ChinaBusiness Wire • 07/20/21
Sesen Bio Announces Positive Outcome From Late-Cycle FDA Meeting For Vicineum ApplicationBenzinga • 07/14/21
Is the Options Market Predicting a Spike in Sesen Bio (SESN) Stock?Zacks Investment Research • 06/18/21